Edwards Lifesciences (NYSE:EW) updated its FY 2021 earnings guidance on Tuesday. The company provided earnings per share guidance of 2.070-2.270 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.130. The company issued revenue guidance of $4.90 billion-$5.30 billion, compared to the consensus revenue estimate of $5.08 billion.Edwards Lifesciences also updated its Q2 2021 guidance to 0.540-0.600 EPS.
Several research analysts have commented on the company. Morgan Stanley raised their target price on Edwards Lifesciences from $99.00 to $108.00 and gave the stock an overweight rating in a research note on Tuesday, April 27th. Atlantic Securities assumed coverage on Edwards Lifesciences in a research note on Wednesday, April 21st. They issued a neutral rating and a $85.00 target price for the company. Wells Fargo & Company raised their target price on Edwards Lifesciences from $87.00 to $93.00 and gave the stock an equal weight rating in a research note on Wednesday, April 21st. Canaccord Genuity raised their target price on Edwards Lifesciences from $94.00 to $103.00 and gave the stock a buy rating in a research note on Tuesday, April 27th. Finally, Piper Sandler raised their price target on Edwards Lifesciences from $97.00 to $105.00 and gave the company an overweight rating in a report on Tuesday, April 27th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $99.93.
EW stock traded down $1.74 during midday trading on Tuesday, reaching $92.89. 96,258 shares of the company traded hands, compared to its average volume of 2,758,865. Edwards Lifesciences has a 52-week low of $66.23 and a 52-week high of $98.11. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.61 and a current ratio of 3.52. The business has a 50 day moving average of $86.76 and a 200-day moving average of $85.01. The firm has a market capitalization of $57.74 billion, a price-to-earnings ratio of 75.70, a P/E/G ratio of 2.61 and a beta of 0.97.
In related news, Director Heisz Leslie Stone sold 6,707 shares of the stock in a transaction that occurred on Friday, April 23rd. The stock was sold at an average price of $97.52, for a total value of $654,066.64. Following the transaction, the director now owns 29,272 shares of the company’s stock, valued at $2,854,605.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Catherine M. Szyman sold 3,389 shares of the stock in a transaction on Tuesday, February 16th. The shares were sold at an average price of $88.20, for a total value of $298,909.80. Following the sale, the vice president now directly owns 30,135 shares in the company, valued at approximately $2,657,907. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 310,003 shares of company stock worth $26,173,339. Company insiders own 1.48% of the company’s stock.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
Featured Story: Nikkei 225 Index
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.